Ocumension Therapeutics

As of December 31, 2025, Ocumension Therapeutics carries a market capitalization of 5.95B, placing it among publicly traded companies globally. Its enterprise value stands at 5.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ocumension Therapeutics's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Ocumension Therapeutics has 803.92M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Ocumension Therapeutics maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Ocumension Therapeutics's stock has declined approximately 40.49% over the past 52 weeks. The 50-day moving average sits at 5.18, while the 200-day moving average is 6.22.

As of December 31, 2025, Ocumension Therapeutics holds 609.31M in cash and equivalents against 208.71M in total debt, resulting in a net debt position of -244.01M. Total book value stands at 4.10B, with working capital of 772.66M providing operational flexibility.